SynthesisJournal of oral rehabilitation2026
Efficacy of Myofascial Release Therapy and Related Soft-Tissue Techniques for Pain in Temporomandibular Disorders: A Systematic Review of Randomized Controlled Trials.
Synthesis in Journal of oral rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis systematic review aimed to evaluate the effectiveness of myofascial release therapy (MFR) on pain in patients affected by myogenous temporomandibular disorders (TMD).
methodsPubMed, Scopus, and Web of Science were searched from inception until 31 January 2026, to identify RCTs including patients affected by TMD as participants, MFR therapy as intervention, and pain intensity as outcome. The risk of bias of studies was assessed with the Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence.
resultsOut of 857 articles, 7 studies were included. All subjects had a diagnosis of TMD performed according to the RDC/TMD or DC/TMD. The rehabilitation period ranged from 10 days to 5 weeks. Treatment frequency ranged from a minimum of one session per week to a maximum of 3 sessions per week. Medium/long-term follow-up was performed in four studies. The Cochrane RoB 2 tool showed that zero studies had a low risk of bias, six had some concerns, and one had a high risk of bias. The GRADE assessment showed a low certain of evidence for pain reduction and mouth function, and a very low certain of evidence in improving QoL.
conclusionsMFR seemed to reduce pain and improve mouth function in patients with myogenous TMD. However, when benchmarked against established clinical thresholds, clinically meaningful efficacy (surpassing the 15-22 mm MCID) is only supported by a subset of the included trials. In this context, MFR could be considered as part of a multidisciplinary approach for patients with TMD. More rigorous isolated-MFR trials are needed to better characterize the efficacy of MFR in patients affected by myogenous TMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.